CharlestonPharma specializes in the development of anti-nucleolin antibodies, particularly their lead product, CP101.2C8, which is a fully human IgG1 monoclonal antibody. This antibody targets nucleolin, a protein found on the surface of various tumor cells, allowing it to enter the cytoplasm where it destabilizes oncogenic mRNAs. By promoting the degradation of these mRNAs, CP101.2C8 induces apoptosis and cell death in a wide range of hematological and solid tumor cell lines. The unique mechanism of action of this antibody, which includes the ability to destabilize multiple oncogenic mRNAs, contributes to its broad-spectrum efficacy against tumors that overexpress nucleolin.

The research and development of CharlestonPharma's anti-nucleolin antibodies are grounded in nearly a decade of preclinical studies, supported by grants from reputable organizations such as the National Cancer Institute and the US Department of Defense. The company has identified nucleolin as a high-value therapeutic target due to its selective expression on cancer cells and its essential role in their survival. Their antibodies have demonstrated potent activity against various solid tumors and hematological malignancies while showing minimal toxicity to normal tissues. Additionally, the ability of these antibodies to exploit nucleolin's shuttling function allows for potential applications in targeted drug delivery, enhancing the therapeutic index of anticancer agents.

United States

CharlestonPharma is a biopharmaceutical company that develops a lead IgG1 monoclonal antibody targeting nucleolin transporter on tumor cells to induce apoptosis and cell death in various cancer cell lines.

CharlestonPharma

Company Details